Iloperidone Benefits Patients With Bipolar I Disorder in Phase 3 Trial
[ad_1] Iloperidone was associated with significant improvement in adults with bipolar I disorder, according to results from a phase 3 study. Iloperidone, an atypical antipsychotic, is currently marketed under the brand name Fanapt for the treatment of schizophrenia in adults. The VP-VYV-683-3201 study (ClinicalTrials.gov Identifier: NCT04819776) evaluated the efficacy and safety of iloperidone in approximately…